FLGT Q4 2024 Earnings — Fulgent Genetics, Inc. Revenue & Financial Results | Market Cap Arena

FLGTFulgent Genetics, Inc.

$458M

Q4 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$76M+8.1% YoY

Gross Profit

$32M41.8% margin

Operating Income

-$16M-21.2% margin

Net Income

-$6M-7.7% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+6.2%

Cash Flow

Operating Cash Flow

$25M

Free Cash Flow

$21M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$91M

Stockholders' Equity

$1.1B

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$71M	+8.1%
Gross Profit	$32M	$25M	+26.2%
Operating Income	-$16M	-$151M	+89.3%
Net Income	-$6M	-$128M	+95.4%

Revenue Segments

Laboratory Services

$141M100%

Geographic Segments

UNITED STATES

$129M85%

Non-US

$11M8%

CHINA

$7M5%

Other Countries

$4M3%